Press Releases

September 27, 2021

Bolden Therapeutics Receives $500,000 Small Business Grant from the National Institute on Aging

PROVIDENCE, RI & CAMBRIDGE, MA. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for potential treatment of CNS diseases such as Alzheimer’s disease, today announced receiving a $500,000 Phase I Small Business Technology Transfer (STTR) grant from the National Institute on Aging of the National Institutes of Health.

February 11, 2021

Bolden Therapeutics Receives Biogen-LabCentral ‘Golden Ticket’ Award

PROVIDENCE, RI. Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for potential treatment of CNS diseases such as Alzheimer’s and ischemic stroke, today announced being awarded the Biogen-LabCentral Golden Ticket.